论文部分内容阅读
充血性心力衰竭(CHF)的治疗目的:一是改善症状(改善健康和生活状况,提高运动耐量),二是提高生存率(预防进行性心力衰竭,心源性猝死和血栓栓塞症).虽然血管扩张剂和新型正性肌力药物能改善CHF病人的心室功能,减轻症状,但对死亡率的降低尚无确切证据.抗心律失常药能明显减少CHF病人的心律失常发生率,但不能减少心源性猝死.1971年Framingham资料表明,CHF出现后5年内死亡机率在男性为62%,在女性为42%;并指出,尽管及早诊断CHF并予有效治疗,而其临床病程和预后仍然极差,一般
The purpose of the treatment of congestive heart failure (CHF) is to improve symptoms (improve health and living conditions, improve exercise tolerance) and to increase survival (prevent progressive heart failure, sudden cardiac death and thromboembolism). Vasodilators and new inotropic agents improve ventricular function and reduce symptoms in CHF patients, but there is no definitive evidence of any reduction in mortality. Antiarrhythmic agents can significantly reduce the incidence of arrhythmias in CHF patients but can not reduce Sudden Cardiac Death. In 1971, Framingham data showed that the risk of dying within five years after CHF onset was 62% for males and 42% for females; and noted that despite the early diagnosis and effective treatment of CHF, the clinical course and prognosis remain very high Poor, average